Drug intelligence / Profile preview

bifidobacterium lactis + inulin

Development stage: Unknown
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

A synbiotic combination comprising the probiotic bacterium *Bifidobacterium lactis* (often classified as *Bifidobacterium animalis* subsp. *lactis*) and the prebiotic fiber inulin. This combination is designed to synergistically promote a healthy intestinal microbiome and enhance systemic immune responses. In clinical research, particularly in vulnerable populations such as infants with cyanotic congenital heart disease (CCHD), the enteral administration of this synbiotic has demonstrated efficacy in reducing the risk of nosocomial sepsis, necrotizing enterocolitis (NEC), and overall mortality. The probiotic component, *B. lactis*, helps maintain gut barrier integrity and competes with pathogenic bacteria, while inulin provides a selective energy source for beneficial bifidobacteria.

Other names: synbiotic

Beyond the preview

Go deeper on bifidobacterium lactis + inulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium lactis + inulin.

Explore the full profile